Current evidence for genetic testing in clopidogrel-treated patients undergoing coronary stenting

Circ Cardiovasc Interv. 2011 Oct 1;4(5):505-13; discussion 513. doi: 10.1161/CIRCINTERVENTIONS.111.962183.
No abstract available

Publication types

  • Review

MeSH terms

  • Aryl Hydrocarbon Hydroxylases / genetics
  • Aryl Hydrocarbon Hydroxylases / metabolism*
  • Biomarkers, Pharmacological / metabolism*
  • Clopidogrel
  • Cytochrome P-450 CYP2C19
  • Genetic Testing* / trends
  • Humans
  • Platelet Aggregation Inhibitors* / pharmacokinetics
  • Platelet Aggregation Inhibitors* / therapeutic use
  • Polymorphism, Genetic
  • Precision Medicine
  • Receptors, Purinergic P2Y12 / metabolism
  • Ticlopidine / analogs & derivatives*
  • Ticlopidine / pharmacokinetics
  • Ticlopidine / therapeutic use
  • Treatment Outcome

Substances

  • Biomarkers, Pharmacological
  • P2RY12 protein, human
  • Platelet Aggregation Inhibitors
  • Receptors, Purinergic P2Y12
  • Clopidogrel
  • Aryl Hydrocarbon Hydroxylases
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19
  • Ticlopidine